This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
This work has been published in the journal ‘ACS applied materials and interface’
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Subscribe To Our Newsletter & Stay Updated
